Tech Center 1600 • Art Units: 1624
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17927222 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Non-Final OA | Merck Sharp & Dohme LLC |
| 17761162 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | Non-Final OA | The Regents of the University of California |
| 18157286 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18047506 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | Final Rejection | Hoffmann-La Roche Inc. |
| 17786239 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 18029057 | MULTI-COORDINATE GOLD-PHOSPHINE COMPOUNDS AND METHOD OF USE | Non-Final OA | University of Kentucky Research Foundation |
| 18498472 | METHOD OF INHIBITING LIPOGENESIS WITH UBIQUITIN-SPECIFIC PEPTIDASE 24 INHIBITOR COMPOSITION | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18012561 | MMP-9 AND MMP-12 INHIBITION FOR TREATING SPINAL CORD INJURY OR RELATED INJURY TO NEUROLOGICAL TISSUE | Final Rejection | The University of Birmingham |
| 17709358 | USE OF COMPOSITION OF IMATINIB OR DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR PREVENTING, TREATING, AND CONTROLLING ADDICTION RELAPSE | Final Rejection | Wuhan University |
| 18011288 | METHOTREXATE ANALOGS AND METHODS OF USE | Non-Final OA | The United States of America, as represented by the Secretary, Dept of Health and Human Services |
| 17889062 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Final Rejection | NURIX THERAPEUTICS, INC. |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | Non-Final OA | LDN Pharma Limited |
| 18545582 | SULFOXIMIDE SUBSTITUTED INDAZOLE IRAK4 KINASE INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | Non-Final OA | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. |
| 18560696 | APPLICATION OF HYDRONIDONE IN PREPARATION OF DRUG FOR TREATING OR PREVENTING CHRONIC HEPATITIS B WITH LIVER FIBROSIS | Non-Final OA | BEIJING CONTINENT PHARMACEUTICALS CO., LTD. |
| 17907463 | COMPOUNDS AND USES THEREOF | Non-Final OA | Foghorn Therapeutics Inc. |
| 18563568 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Non-Final OA | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI |
| 18551059 | TASIPIMIDINE FORMULATIONS AND USE THEREOF | Non-Final OA | ORION CORPORATION |
| 18373904 | TREATMENT OF MENTAL DISORDERS | Non-Final OA | GH Research Ireland Limited |
| 18255476 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Non-Final OA | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 18283121 | COMPOUND HAVING SULFONATE GROUP AND PHOTOELECTRIC CONVERSION ELEMENT USING SAME | Non-Final OA | HODOGAYA CHEMICAL CO., LTD. |
| 18550958 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | Non-Final OA | ACONDICIONAMIENTO TARRASENSE |
| 18550907 | METHODS AND COMPOSITIONS FOR TREATING EYE DISEASES | Non-Final OA | JENIVISION INC. |
| 18011741 | Crystalline Form of Compound | Non-Final OA | Shenzhen Forward Pharmaceuticals Co., Limited |
| 18043419 | COMPOUND FOR INHIBITING MUTANT EGFR AND USE THEREOF | Non-Final OA | East China University of Science and Technology |
| 18131979 | USE OF HISTONE ACETYLTRANSFERASE INHIBITOR AMIDOXIMES AS ANTI-PROLIFERATIVE AGENTS | Non-Final OA | Texas Woman’s University |
| 17941854 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Final Rejection | SERVIER PHARMACEUTICALS LLC |
| 18124519 | THERAPEUTIC COMPOSITIONS, COMPONENTS AND METHODS OF PREPARATION AND USE THEREOF | Final Rejection | Unique Flower LLC |
| 18246034 | NOVEL N-HETEROCYCLIC BET BROMODOMAIN INHIBITOR, AND PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | Non-Final OA | Chengdu Easton Biopharmaceuticals Co., Ltd. |
| 18173349 | STABILIZATION OF ACETAMINOPHEN IN AQUEOUS SOLUTION | Non-Final OA | Nostrum Pharmaceuticals, LLC |
| 17906650 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Final Rejection | Akebia Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy